Eli Lilly and Company (LLY) Stock Analysis
Eli Lilly and Company (LLY) is a multinational pharmaceutical manufacturer with a portfolio spanning cardiometabolic health, oncology, and immunology. The company has gained significant investor attention due to blockbuster products like Mounjaro (diabetes/obesity) and a strong pipeline, making it a frequent research subject for healthcare-focused investors.
Get a full AI research report on LLY
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does Eli Lilly and Company do?
Eli Lilly discovers, develops, manufactures, and markets human pharmaceutical products globally, with major revenue streams from insulin products (Humalog, Humulin), diabetes treatments (Mounjaro, Trulicity, Jardiance), obesity medication (Zepbound), cancer therapies (Cyramza, Erbitux, Verzenio), and immunology drugs (Olumiant, Taltz). The company operates across the United States, Europe, China, Japan, and other international markets. Revenue is generated primarily through direct sales to healthcare systems, pharmacies, and patients via insurance coverage.
Bull case
- ✓Mounjaro and Zepbound address massive addressable markets in type 2 diabetes and obesity, with strong early adoption and limited direct competition in the GLP-1 class.
- ✓Gross margin of 83.4% and operating margin of 54.2% demonstrate significant pricing power and operational efficiency in the pharmaceutical industry.
- ✓Forward P/E of 27.1x is substantially lower than the trailing P/E of 41.2x, suggesting market expectations for earnings growth to justify current valuation.
- ✓Diversified product portfolio across three major therapeutic areas reduces dependency on any single drug and provides multiple growth vectors.
Bear case
- ✗Trailing P/E ratio of 41.2x is elevated relative to historical pharma averages, reflecting high growth expectations that may not materialize.
- ✗High debt-to-equity ratio of 162.1% indicates substantial leverage, which increases financial risk if revenue growth slows or interest rates remain elevated.
- ✗Quick ratio of 0.679 suggests potential near-term liquidity constraints, as the company holds less than $0.68 in liquid assets per dollar of current liabilities.
- ✗Patent cliffs on major products and increasing competition from biosimilars and generic alternatives pose long-term revenue risks.
- ✗Regulatory scrutiny on drug pricing and potential reimbursement pressure could impact margins and market access for key products.
LLY valuation & financial health
Eli Lilly trades at a trailing P/E of 41.2x with a forward P/E of 27.1x, indicating the market is pricing in significant near-term earnings growth. The PEG ratio of 1.48 suggests the stock is trading at a modest premium to growth expectations. The company maintains strong profitability metrics with a net margin of 33.5% and ROA of 20.4%, though ROE of 102.3% appears inflated due to high leverage. The debt-to-equity ratio of 162.1% is notably elevated for a mature pharmaceutical company, while the current ratio of 1.36 and quick ratio of 0.68 indicate adequate but not exceptional liquidity. The EV/EBITDA multiple of 28.5x reflects premium valuation relative to the broader market.
The bottom line
Eli Lilly presents a complex investment profile balancing strong fundamental growth drivers (Mounjaro, obesity market opportunity, diversified pipeline) against elevated valuation multiples and financial leverage. Key factors to weigh include whether forward earnings growth justifies the 27x forward P/E, the sustainability of Mounjaro's market position against emerging competitors, and the company's ability to service its 162% debt-to-equity ratio amid potential pricing pressures. Investors should monitor quarterly revenue trends, competitive dynamics in the GLP-1 market, regulatory developments on drug pricing, and management's capital allocation decisions regarding debt reduction versus R&D investment.
Frequently asked questions
What does Eli Lilly and Company do?
Eli Lilly discovers, develops, and markets pharmaceutical products across three main areas: cardiometabolic health (insulin, diabetes, and obesity treatments), oncology (cancer therapies), and immunology (rheumatoid arthritis, atopic dermatitis, and other conditions). The company operates globally with manufacturing and sales in the U.S., Europe, China, Japan, and other markets.
Is LLY overvalued at current prices?
LLY trades at a trailing P/E of 41.2x and forward P/E of 27.1x. Whether this represents fair value depends on your growth assumptions; the forward multiple suggests the market expects significant earnings expansion, while the PEG ratio of 1.48 indicates modest premium relative to growth rates. Valuation is ultimately subjective and depends on individual risk tolerance and time horizon.
What are LLY's main revenue drivers?
Key products include Mounjaro and Zepbound (diabetes and obesity), Trulicity and Jardiance (type 2 diabetes), insulin products (Humalog, Humulin), and oncology drugs like Verzenio and Cyramza. Mounjaro has emerged as a major growth driver due to strong demand in the diabetes and obesity markets.
What is LLY's dividend yield?
Eli Lilly offers a dividend yield of 0.56% with a payout ratio of 21.7%, indicating the company retains most earnings for reinvestment in R&D and growth initiatives rather than returning capital to shareholders through dividends.
What are the main risks for LLY investors?
Key risks include high valuation multiples, elevated debt-to-equity ratio of 162%, patent cliffs on major products, competitive pressure from biosimilars and generics, regulatory scrutiny on drug pricing, and the concentration of growth expectations on a few products like Mounjaro.
How does LLY's profitability compare to peers?
LLY demonstrates strong profitability with a gross margin of 83.4%, operating margin of 54.2%, and net margin of 33.5%, which are generally favorable for the pharmaceutical industry. However, these metrics should be compared against specific competitors and industry benchmarks to assess relative performance.
Research LLY with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.